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SUMMARY
Human pluripotent stem cells (hPSCs) provide an unlimited source for generating various kinds of functional blood cells. However, effi-
cient strategies for generating large-scale functional blood cells from hPSCs are still lacking, and the mechanism underlying human he-
matopoiesis remains largely unknown. In this study, we identified myeloid ectopic viral integration site 1 homolog (MEIS1) as a crucial
regulator of hPSC early hematopoietic differentiation. MEIS1 is vital for specification of APLNR+mesoderm progenitors to functional he-
mogenic endothelial progenitors (HEPs), thereby controlling formation of hematopoietic progenitor cells (HPCs). TAL1 mediates the
function of MEIS1 in HEP specification. In addition, MEIS1 is vital for megakaryopoiesis and thrombopoiesis from hPSCs. Mechanisti-
cally, FLI1 acts as a downstream gene necessary for the function of MEIS1 duringmegakaryopoiesis. Thus, MEIS1 controls human hema-
topoiesis in a stage-specific manner and can be potentially manipulated for large-scale generation of HPCs or platelets from hPSCs for
therapeutic applications in regenerative medicine.
INTRODUCTION
Hematopoietic stem cell (HSC) transplantation has success-
fullybeenusedtotreatpatients suffering fromhematopoietic
diseases and malignancies. However, the availability and
immunological incompatibility of HSCs limit their clinical
applications (Copelan, 2006). Human pluripotent stem cells
(hPSCs), includinghumanembryonic stemcells (hESCs) and
human induced pluripotent stem cells (hiPSCs), are capable
of long-term proliferation and can differentiate into all three
embryonic germ layers in vitro, providing a potential renew-
able source for generating transplantable HSCs (Inoue et al.,
2014). However, despite considerable progress in methods
of optimizing hematopoietic differentiation, the efficient
generation ofHSCs and other genuine functional blood cells
fromhPSCs has been unsuccessful (Kaufman, 2009; Slukvin,
2016;Vo andDaley, 2015). Therefore, a better understanding
of the hematopoietic differentiation progress of hPSCs
and its regulatory mechanism is highly demanded before
adequate numbers of robustly transplantable HSCs or other
functional blood cells from hPSCs can be generated.
Hematopoietic differentiation from hPSCs goes through a
sequential series of cell-fate decisions, including specifica-
tion of mesoderm, lateralization of mesoderm, formation
of thehemogenic endotheliumprogenitors (HEPs), and gen-
erationof hematopoietic progenitors through endothelial to
hematopoietic transition (Slukvin, 2016). The differentia-
tion process can be monitored by the sequential onset of
markers including BRACHYURY, APLNR, CD31/CD34, and
CD43/CD45 (Slukvin, 2016). Each stage in hematopoietic
differentiation fromhPSCs is precisely regulated by different
transcriptional factors. Our study has demonstrated that
MSX2 is essential for the induction of mesoderm from
hPSCs (Wu et al., 2015). The reciprocal repression of
NANOG and CDX2 directs mesoderm specification into
anterior and posterior subtypes (Mendjan et al., 2014). It
has been shown that ectopic expression of RUNX1a pro-
motes hematopoietic commitment of hESCs by increasing
the expression of mesoderm and hematopoietic develop-
ment-associated genes (Ran et al., 2013). TAL1 has been re-
ported to promote hematopoietic differentiation of hPSCs
through accelerating the generation of HEPs (Real et al.,
2012). In line with the critical roles of transcription factors
in hematopoietic specification from hPSCs, a recent study
demonstrates that the combination of GATA2/ETV2 or
GATA2/TAL1 can directly program hPSCs to hemogenic
endothelium-like cells with distinct hematopoietic poten-
tial (Elcheva et al., 2014). Therefore, exploring novel tran-
scription factors implicated in hematopoietic commitment
of hPSCs is highly beneficial for large-scale production of
transplantable HSCs from hPSCs in vitro.
MEIS1 (myeloid ectopic viral integration site 1 homolog)
belongs to the MEIS subfamily of TALE (three-amino-acid
loop extension) homeodomain-containing transcription
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factors. MEIS1 was first identified in BXH-2 leukemic mice,
and its aberrant overexpression is required for the induc-
tion and maintenance of MLL-fusion-induced leukemia
(Collins and Hess, 2016). MEIS1 shows high expression in
HSCs and is downregulated during differentiation except
in the megakaryocytic lineage in which it is highly ex-
pressed (Pineault et al., 2002). Meis1-deficient zebrafish
presents severely impaired primitive and definitive hema-
topoiesis (Cvejic et al., 2011). Mice lacking Meis1 show
extensive hemorrhaging in the trunk and die at embryonic
day 14.5. Furthermore, the number of HSCs in Meis1/
fetal liver is dramatically reduced, and the cells fail to pro-
tect lethally irradiated mice (Azcoitia et al., 2005; Gonza-
lez-Lazaro et al., 2014; Hisa et al., 2004), suggesting the
essential role of Meis1 in early mouse hematopoiesis. How-
ever, the stage at which Meis1 regulates early hematopoie-
sis and the underlyingmechanism remain to be elucidated.
In addition, the role ofMEIS1 in early hematopoietic differ-
entiation in humans is still undefined.
The embryonic lethality observed in Meis1/ mice re-
sults from failure of lymphatic-venous separation during
embryonic angiogenesis due to the absence of megakaryo-
cytes (Carramolino et al., 2010). Elevated expression of
Meis1 inmouse embryonic stem cells promotesmegakaryo-
cytic progenitor differentiationwhile suppressing erythroid
progenitor development at the megakaryocyte-erythroid
progenitor (MEP) stage (Cai et al., 2012).MEIS1 overexpres-
sion directs human hematopoietic progenitor cells (HPCs)
toward the MEP fate and enhances megakaryocytic colony
formation ability (Zeddies et al., 2014). Although these
studies demonstrate the importance of MEIS1 in megakar-
yocytic differentiation, the precise roles of MEIS1 in mega-
karyocyticmaturation, platelet formation, and the underly-
ing mechanisms remain to be defined.
In this study, by taking advantage of a chemical-defined
hematopoietic differentiation model, whole-genome gene
profiling and the CRISPR/CAS9 technology, we identified
MEIS1 as a crucial regulator for hPSC differentiation into
functional hematopoietic cells. We also found that MEIS1
regulates hematopoietic differentiation in a stage-specific
manner and by targeting the transcription factors TAL1
and FLI1. Together, we define a role of MEIS1 in human
development, unveil newmechanisms for human hemato-
poiesis, and contribute potential new strategies to regener-
ative medicine.
RESULTS
MEIS1 as a Potential Regulator of Early Human
Hematopoietic Differentiation
To identify key regulators of human early hematopoietic
differentiation, we induced directed hematopoietic differ-
entiation of H1 hESCs in a chemically defined system
(CDS) by using a previously reported strategy with
modifications (Pang et al., 2013; Wang et al., 2012) (Fig-
ure S1A). We performed time course RNA sequencing
(RNA-seq) analysis in hESC samples collected from day
0 to day 4 after differentiation. Gene set enrichment
analysis (GSEA) demonstrated that hematopoiesis-related
genes were significantly enriched in the differentiated cells
at day 4 compared with undifferentiated cells, thus vali-
dating our screening strategy for hematopoietic gene
screening (Figure 1A). To identify key transcription factors
governing differentiation, 68 transcriptional factors upre-
gulated gradually and steadily during early hematopoietic
differentiation of H1 hESCs were selected (see Table S5).
After 4 days of differentiation, the mRNA levels of all these
factors increased by more than 10-fold (Figure 1B and
Table S5; false discovery rate [FDR] < 0.01). Interestingly,
several previously reported genes crucial for mammalian
hematopoiesis such as GATA2, HOXA9, GFI1, HOXA7,
and HOXA5 were identified (Dou et al., 2016; Huang
et al., 2015; Ramos-Mejia et al., 2014; Sandler et al.,
2014), thereby validating the screening strategy (Figure 1B).
We were particularly interested in MEIS1 because of its
previously documented roles in leukemogenesis and early
hematopoiesis in animals (Azcoitia et al., 2005; Collins
and Hess, 2016).
We first confirmed MEIS1 upregulation during early he-
matopoietic differentiation of bothH1hESCs and anhiPSC
line, BC1 (Chou et al., 2011) (Figure 1C). MEIS1 upregula-
tion was also observed in H1 and BC1 cells induced to un-
dergo hematopoietic differentiation in the presence of the
mouse AGM-S3 (mAGM-S3) feeder cells (Figure 1D), which
have been shown to efficiently induce hematopoietic dif-
ferentiation of hPSCs (Mao et al., 2016). With this method,
CD43+ and CD45+ HPCs can be generated in a stepwise
manner (Figure S1B). Furthermore, in both CDS and
mAGM-S3 co-culture systems, CD43+ cells could further
differentiate into CD45+ hematopoietic cells (Figure S1C)
and generated all types of hematopoietic colonies
including BFU-E, CFU-E, CFU-GM, and CFU-GEMM (Fig-
ure S1D). These data demonstrated that both methods led
us to successfully generate functional hematopoietic cells
from hPSCs. We therefore further measured the expression
ofMEIS1 in different populations of hematopoietic cells. In
CD43+ and CD45+ hematopoietic cells derived from H1
and BC1 cells,MEIS1 showed expression levels comparable
to that in human cord-blood-derived CD34+ cells. In
contrast, MEIS1 expression was nearly undetectable in un-
differentiated cells (Figures 1E and 1F). In addition, we also
detected the expression of other hematopoietic differentia-
tion-associated transcriptional factors listed in Figure 1B.
As shown in Figure S1E, GATA2 and GFI1 showed com-
parable expression levels in the hematopoietic cells derived
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from hPSCs and the CD34+ cells isolated from human cord
blood. However, the expression of HOXA genes (HOXA5,
HOXA7, and HOXA9) in the hematopoietic cells derived
from hPSCs was obviously lower than that of the CD34+
cells isolated from human cord blood. Consistent with
our results, low expression of HOXA genes can also be
found in published transcriptome analysis of hPSC-derived
hematopoietic cells (Dou et al., 2016; Ferrell et al., 2015; Ng
et al., 2016). Thus, we identified MEIS1 as a potential regu-
lator of early hematopoietic differentiation in hPSCs.
MEIS1 Deletion Impairs Early Hematopoietic
Differentiation
We next addressed the potential role of MEIS1 in hemato-
poietic specification of hPSCs.We created targeted deletion
for the MEIS1 gene in H1 hESCs and BC1 cells using the
CRISPR/CAS9 technology. Small guide RNAs (sgRNAs) tar-
geting different exons of the human MEIS1 gene were de-
signed and tested for their genome editing efficacy (Figures
2A, S2A, and S2B). After several clone picking selections, we
generated cell clones with homozygous MEIS1 deletion
in both H1 hESCs and BC1 cells with E3G1 sgRNA. Expres-
sion of MEIS1 was completely absent (Figure 2B), while
sequencing analysis confirmed frameshifts due to deletion
or insertion (Figure 2C). We also included a MEIS1 hetero-
zygous clone derived from H1 hESCs in parallel with the
MEIS1 homozygous clones for future analyses.
MEIS1 deletion hadno effect onhPSCpluripotency. Both
MEIS1/H1 cells andMEIS1/ BC1 cells grew as compact
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Figure 1. MEIS1 as a Potential Regulator
of Early Hematopoietic Differentiation
of hPSCs
(A) GSEA comparison of the differentiated
cells at day 4 with undifferentiated cells:
the enrichment of genes involved in regu-
lation of hematopoiesis (top) and positive
regulation of hematopoiesis (bottom) in the
differentiated cells at day 4. NES, normal-
ized enrichment score.
(B) Heatmaps of gradually increased tran-
scriptional factors during early hematopoi-
etic differentiation from H1 hESCs. RNA-
seq analysis was performed on samples
collected at day 0, day 2, day 3, and day 4 of
differentiation.
(C and D) Time course analysis of MEIS1
expression during hematopoietic differen-
tiation of hESCs (H1) or hiPSCs (BC1) under
chemically defined condition (C) or in
mAGM-S3 co-culture (D).
(E and F) Real-time PCR analysis of MEIS1 in
CD34+ cells from human cord blood and the
hematopoietic cells derived from H1 or BC1
cells under chemically defined condition
(E) or cultured with the mAGM-S3 co-culture
system (F). Relative expression is normal-
ized to the level (= 1) of mRNA in undif-
ferentiated H1 or BC1 cells.
Error bars represent mean ± SEM of samples
from three independent experiments.
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western blot, and immunofluorescence analyses further
showed that MEIS1 deletion did not alter the expression
of pluripotency markers such as NANOG, OCT4, and
SOX2 (Figures 2D, 2E, and S2C).
In contrast, MEIS1 deletion profoundly impaired he-
matopoietic differentiation of hPSCs. In experiments
with the mAGM-S3 co-culture system, MEIS1 deletion
reduced the number of CD43+ HPCs by 2-fold, as assessed
with flow cytometry and immunofluorescence analysis
in both H1 cells (wild-type [WT] 9.17% ± 0.65%
versus MEIS1/ 4.20% ± 0.52%, p < 0.01) and BC1 (WT
5.57% ± 0.42% versus MEIS1/3.03% ± 0.07%, p < 0.05)
cells (Figures 3A and S2D). Similar decrease in CD43+
HPCs was observed in cells produced under the CDS condi-
tion (H1, WT 5.20% ± 0.15% versus MEIS1/ 2.24% ±
0.27%, p < 0.001; BC1,WT 7.84% ± 0.62% versusMEIS1/
3.44% ± 0.48%, p < 0.01) (Figure S2E). To further demon-
strate that MEIS1 deletion impairs hematopoietic differen-
tiation of hPSCs, we measured the induction of CD45+ he-
matopoietic cells, which arise from CD43+ HPCs (Slukvin,
2016). Indeed, the number of CD45+ cells was much lower
with MEIS1 deletion in both H1 hESCs (H1 WT 7.70% ±
0.76% versus H1 MEIS1/ 2.55% ± 0.92%, p < 0.05) and
BC1 cells (BC1 WT 5.06% ± 0.36% versus BC1 MEIS1/
2.48% ± 0.20%, p < 0.01) (Figure 3B). The decrease in
CD43+ and CD45+ HPCs was also observed in MEIS1 het-
erozygous cells (Figures 3A and 3B). Thus, MEIS1 deletion
impairs hematopoietic differentiation of hPSCs.
MEIS1 Deletion Suppresses HEP Specification
The decrease in production of hematopoietic cells from




B Figure 2. Establishment of MEIS1-
Deleted hPSC Lines Using the CRISPR/
CAS9 Technology
(A) Schematics of the Cas9/sgRNA-target-
ing sequences at the human MEIS1 locus.
(B) Western blotting analysis of MEIS1 in
H1, H1 MEIS1+/, and H1 MEIS1/ cells or
BC1 and BC1 MEIS1/ cells. WT and MEIS1-
deleted hPSCs were treated with 10 mM
retinoic acid for 4 days. Tubulin was used as
a loading control.
(C) DNA-sequencing results of H1 MEIS1+/,
H1 MEIS1/, and BC1 MEIS1/ cells.
(D) Real-time PCR analysis of POU5F1, SOX2,
and NANOG in undifferentiated H1, H1
MEIS1+/, and H1 MEIS1/ cells or BC1
and BC1 MEIS1/ cells. Relative expression
is normalized to the level (= 1) of mRNA in
H1 or BC1 cells.
(E) Western blotting analysis of OCT4, SOX2,
and NANOG in undifferentiated H1, H1
MEIS1+/, and H1 MEIS1/ cells or BC1
and BC1 MEIS1/ cells. Tubulin was used
as a loading control.
Error bars represent mean ± SEM of samples
from three independent experiments. NS,
not significant.
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suppressed proliferation or increased apoptosis of hemato-
poietic cells or (2) decreased generation of hematopoietic
cell precursors. To distinguish between these possibilities,
we assessed the rates of proliferation and apoptosis of
CD43+ HPCs. No significant changes in the fraction of
cycling or apoptotic cells were detected in CD43+ hemato-
poietic cells with MEIS1 deletion in both H1 hESCs and
BC1 cells (Figures S2F and S2G). These results led us to hy-
pothesize that the impaired generation of early hematopoi-
etic cell precursors with MEIS1 deletion might result from
decreased numbers of CD43+ and CD45+ HPC generation.
The entire hematopoietic differentiation process from
H1 hESCs could be monitored in both the CDS and
the mAGM-S3 culture system (Figures 3C and S1A).
Furthermore, CD31+CD34+ cells derived from H1 hESCs
could further differentiate into both endothelial cells
and hematopoietic cells in the OP9 co-culture model













































































































































































Figure 3. MEIS1 Deletion Impairs Early
Hematopoietic Differentiation of hPSCs
by Suppressing HEP Specification
(A) Flow cytometry analysis of the percent-
age of CD43+ hematopoietic precursors at
day 7 of differentiation from WT and MEIS1-
deleted hPSCs in mAGM-S3 co-culture.
(B) Flow cytometry analysis of the per-
centage of CD45+ blood cells at day 12 of
differentiation from WT and MEIS1-deleted
hPSCs in mAGM-S3 co-culture.
(C) Representative flow cytometry dot plots
showing the sequential emergence of
brachyury+ mesoderm cells, APLNR+ lateral
mesoderm cells, CD31+CD34+ HEPs, and
CD43+ hematopoietic cells during hPSC he-
matopoietic differentiation in the mAGM-S3
co-culture system.
(D) Flow cytometry analysis of the percent-
age of APLNR+ lateral mesoderm cells at day 3
of differentiation fromWTandMEIS1-deleted
hPSCs in mAGM-S3 co-culture system.
(E) Flow cytometry analysis of the per-
centage of CD31+CD34+ HEPs at day 5 of
differentiation from WT and MEIS1-deleted
hPSCs in mAGM-S3 co-culture.
(F) Schematic diagram showing the HEP po-
tential analysis of APLNR+ cells at day 3 of
differentiation inmAGM-S3co-culture system.
FACS, fluorescence-activated cell sorting.
(G) Flow cytometry analysis of the per-
centage of CD31+CD34+ HEPs transited from
APLNR+ cells.
(H) Flow cytometry analysis of the percent-
age of APLNR+ lateral mesoderm cells at day
3 of differentiation from H1 hESCs without
doxycycline (Dox ) or with 1 mg/mL
doxycycline (Dox +), which induces MEIS1
expression in mAGM-S3 co-culture.
(I) Flow cytometry analysis of the percentage
of CD31+CD34+ HEPs at day 5 of differentia-
tion from H1 hESCs without or with MEIS1
overexpression in mAGM-S3 co-culture.
Error bars represent mean ± SEM of samples
from three independent experiments. NS,
not significant, *p < 0.05, **p < 0.01, and
***p < 0.001.
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CD31+CD34+ cells generated in both cultures are func-
tional intact HEPs. No significant changes in the fraction
of brachyury+ mesoderm cells or APLNR+ lateral mesoderm
cells were observed with MEIS1 deletion (Figures 3D and
S3B). In contrast, MEIS1 deletion in H1 hESCs caused the
population of CD31+CD34+ HEPs to reduce by approxi-
mately 3-fold (2.39% ± 0.17% versus 0.86% ± 0.05%,
p < 0.01) (Figure 3E, left). A similar decrease was also
observed in BC1 cells (Figure 3E, right). Similar decreases
in CD31+CD34+ HEPs were also observed in H1 hESCs
and BC1 cells under CDS conditions (Figure S3C). Further-
more, the defects of HEP generation caused by MEIS1 dele-
tion could be rescued by forced expression of MEIS1
(Figure S3D).
To directly test whether MEIS1 deletion impairs HEP
specification, we sorted APLNR+ cells and induced them
to HEPs by adding vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF) to the cul-
ture (Figure 3F). As expected, MEIS1 deletion profoundly
inhibited the transition of CD31+CD34+ HEPs from
APLNR+ cells (Figure 3G). Interestingly, MEIS1 level was
much higher in CD31+CD34+ cells than in APLNR+ cells
derived from H1 hESCs and BC1 cells (Figure S3E).
Finally, we asked whether MEIS1 plays a causal role in
HEP specification, and we overexpressed MEIS1 in H1
hESCs. MEIS1 overexpression significantly enhanced the
production of CD31+CD34+ HEPs while exerting little
effect on APLNR+ cell induction (Figures 3H and 3I).
Together, our findings demonstrated that MEIS1 acts as a
pivotal regulator of hPSC early hematopoietic differentia-
tion and specifically controls HEP specification from
APLNR+ lateral mesoderm cells.
MEIS1 Controls HEP Specification by Targeting TAL1
To investigate the molecular mechanism by which MEIS1
controls HEP specification, we performed RNA-seq analysis
of cells undergoing HEP transition, with or without MEIS1
deletion. After differentiation, a large number of genes
were downregulated inMEIS1-deleted H1 hESCs compared
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Figure 4. MEIS1 Regulates the Specifica-
tion of HEP Cells by Targeting TAL1
(A) Heatmaps of 70 downregulated genes
in cells differentiated from H1-MEIS1/
compared with those from differentiated H1
cells.
(B) Real-time PCR analysis of TAL1 in cells
differentiated from WT and MEIS1-deleted
hPSCs at day 3 of differentiation in chemi-
cally defined medium.
(C and D) Time course analysis of gene
expression of MEIS1 and TAL1 in H1 (C) or
BC1 (D) during hematopoietic differentia-
tion in chemically defined medium with
real-time PCR. All values are normalized to
the level (= 1) of mRNA in cells cultured in
mTeSR1 before differentiation (0 hr).
(E) Expression of FLAG-MEIS1 protein in
hPSCs infected with a lentivirus carrying the
MEIS1-2A-GFP cassette. Vector carrying
only GFP was used as a control.
(F) Flow cytometry analysis of the percent-
age of CD31+CD34+ HEPs differentiated
from WT and MEIS1-deleted hPSCs without
or with TAL1 overexpression. GFP+ gated
events are shown.
Error bars represent mean ± SEM of samples
from three independent experiments. NS,
not significant, *p < 0.05 and **p < 0.01.
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those, a number of mammalian hematopoiesis-associated
genes such as FLI1, APLN, TAL1, and MYB were signifi-
cantly downregulated, again showing that hematopoiesis
was impaired with MEIS1 deletion. Decreased gene expres-
sion of FLI1, APLN, TAL1, andMYBwas further validated in
both H1 hESCs and BC1 cells with real-time PCR analysis
(Figure 4B). Due to their previously documented roles in
human hematopoiesis (Real et al., 2012; Yu et al., 2012),
we hypothesized that APLN or TAL1 might mediate the
function of MEIS1 during HEP specifications. To test this
hypothesis, we first applied APLN directly to MEIS1/
H1 hESCs induced to undergo hematopoietic differentia-
tion. Surprisingly, APLN addition failed to rescue the
decrease in CD31+CD34+ HEPs caused by MEIS1 deletion
(Figure S4A). We next focused on the role of TAL1 in medi-
ating the function of MEIS1. Time course analysis revealed
that MEIS1 was upregulated within 36–48 hr and by
approximately 10-fold at 48 hr after differentiation, when
APLNR+ lateral mesoderm cells emerged (Figure 4C). In
contrast, TAL1 began to increase after 60–72 hr of differen-
tiation induction. Similar results were observed in BC1 cells
(Figure 4D). In addition, MEIS1 was significantly upregu-
lated in APLNR+ cells compared with undifferentiated
hPSCs. In contrast, expression of TAL1 was extremely low
with little difference between APLNR+ cells and undifferen-
tiated hPSCs (Figures S4B and S4C). These results suggested
that the expression of MEIS1 preceded the induction
of TAL1 expression during hPSC early hematopoietic
differentiation. Meanwhile, forced expression of MEIS1
significantly increased the level ofTAL1 at day 3 after differ-
entiation (Figure S4D), further implying that MEIS1 might
act as a potential upstream regulator of TAL1. We next
tested the role of TAL1 by expressing TAL1-2A-GFP in
hPSCs via lentiviral infection. Overexpression of TAL1
at both the protein and the mRNA level in H1
hESCs and BC1 cells was verified (Figures 4E and S4E).
Strikingly, flow cytometry analysis demonstrated that
TAL1 overexpression completely reversed the decrease in
CD31+CD34+ HEPs caused by MEIS1 deletion in both H1
hESCs and BC1 cells (Figure 4F). Thus, TAL1 mediates the
function of MEIS1 in converting APLNR+ cells to HEPs dur-
ing hPSC hematopoietic differentiation.
MEIS1/ Megakaryocytes Fail to Undergo
Polyploidization
The important roles of MEIS1 in hPSC early hematopoietic
differentiation ledus to askwhether itmight play additional
roles in HPC differentiation into multilineage functional
blood cells. We enriched CD43+ HPCs produced after
12-day differentiation from hPSCs and assessed their
behavior in the colony-formingunit (CFU) assay, andno sig-
nificant differences in colony numbers and types were de-
tected in cells with or without MEIS1 deletion (Figure S5A).
It was previously reported that Meis1 deletion disrupts
the generation of megakaryocytes in vivo (Azcoitia et al.,
2005; Carramolino et al., 2010; Gonzalez-Lazaro et al.,
2014; Hisa et al., 2004), leading us to determine the mega-
karyocytic potential of MEIS1/ HPCs in a more special-
ized culture system containing thrombopoietin (TPO) and
other cytokines. This was also because the CFU assay was
not well suited for assessing the differentiation potential
of HPCs to the megakaryocytic lineages. In this culture sys-
tem, large differentiated cells emerged at day 3 and peaked
in number at day 6, while proplatelets were also observed
at day 6 (Figure S5B). Flow cytometry, May-Gru¨nwald Gi-
emsa (MGG) staining, and the spreading assay further
confirmed the generation of functional megakaryocytes
(Figures S5B and S5C). Similar to platelets from peripheral
blood, hPSC-derived platelet-sized particles (PLPs) re-
sponded normally to agonist stimulation as demonstrated
by adhesion, spreading, aggregation, and a-granule release
(Figures S5D–S5G), indicating that hPSC-derived megakar-
yocytes in our systems can produce viable and functional
intact PLPs. Interestingly, MEIS1 was upregulated during
the process (Figure S5H), suggesting that it might also play
a role in megakaryocytic differentiation. Indeed, by using
flow cytometry and immunostaining, we found that
MEIS1 deletion robustly inhibited the generation of
CD41a+CD42b+ megakaryocytes in both differentiating
H1 hESCs and BC1 cells (Figures 5A and S6A). In addition
to the overall decrease in CD41a+CD42b+ megakaryocytes,
quantification of cell diameters demonstrated that MEIS1-
deleted cells differentiated from HPCs were much smaller
compared with the WT cells (H1 hESCs 18.86 ± 0.45 mm
versus 29.07 ± 0.66 mm; BC1 cells 20.06 ± 0.48 mm versus
29.33 ± 0.78 mm, p < 0.001, n = 100) (Figures 5B and S6B).
The decrease in cell volume with MEIS1 deletion was also
shown in experiments with flow cytometry (Figure 5C).
Thus, MEIS1 is pivotal for hPSC megakaryocytic
differentiation.
The decrease in cell size caused by MEIS1 deletion sug-
gested that the CD41+ megakaryocytes produced from
MEIS1/ HPCs might fail to mature properly. In general,
the process of megakaryocyte maturation consists of three
major steps: the emergence and expansion of the demarca-
tion membrane system (DMS), polyploidization mediated
by endomitosis, and production of proplatelets followed
by the release of platelets (Machlus and Italiano, 2013).
To reveal the ultrastructure of the megakaryocytes derived
from hPSCs, we used thin-section electron micrography
to observe granules, mitochondria, DMS, and lobulated
nuclei, allowing us to clearly visualize these structures
in WT hPSC-derived megakaryocytes (Figure S6C, left).
In contrast, the granules and DMS in MEIS1/ mega-
karyocytes were largely absent (Figure S6C, right), sug-
gesting defects in the differentiation program.We therefore
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determined polyploidization in hPSC-derived megakaryo-
cytes with or without MEIS1 deletion. MGG staining
showed that large-size megakaryocytes with high degree
of polyploidy were generated from WT H1 hESCs and
BC1 cells (Figure 5D). In contrast, the megakaryocytes
derived from MEIS1/cells were much smaller in size
andmostly contained two or even fewer nuclei (Figure 5D).
Analysis of DNA content further revealed that most mega-
karyocytes differentiated from MEIS1/ H1 hESCs were
arrested at 2N or 4N stage, with very few cells beyond
>8N stage (R8N, WT 36.56% ± 2.31% versus
MEIS1/1.86% ± 0.72%, p < 0.001) (Figures 5E and S6D,
left). The same deficiency was also observed in megakaryo-
cytes derived from BC1 cells (R8N, WT 43.52% ± 5.90%
versus MEIS1/ 1.76% ± 1.27%, p < 0.001) (Figures 5E
and S6D, right). Together, our results demonstrated that
MEIS1 is vital for DMS development and polyploidization
during megakaryocyte maturation.
MEIS1 Deletion Abolishes Thrombopoiesis
Because DMS development and polyploidization are indis-






Figure 5. Megakaryocytes Generated
from MEIS1/ HPCs Fail to Undergo
Polyploidization
(A) Flow cytometry analysis of the per-
centage of CD41a+CD42b+ megakaryo-
cytes at various stages of megakaryocytic
differentiation.
(B) Distribution of cell sizes (100 cells) in
eachgroup asmeasuredby a hemocytometer.
(C) The cell size at day 3 of megakaryo-
cytic differentiation as measured by flow
cytometry.
(D) Morphology analysis of megakaryocytes
at day 3 of megakaryocytic differentiation
by MGG staining (scale bar, 20 mm).
(E) Ploidy distribution of megakaryocytes at
day 3 of megakaryocytic differentiation was
analyzed by staining cellular DNA with
propidium iodide.
Error bars represent mean ± SEM of samples
from three independent experiments. NS,
not significant, *p < 0.05, **p < 0.01,
***p < 0.001. MK, megakaryocytic.
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ofMEIS1deletion on thrombopoiesis.While a largenumber
of proplatelet-forming megakaryocytes were found from
WT H1 hESCs and BC1 cells (Figure 6A, Movie S1), no pro-
platelets were detected in megakaryocytes derived from
MEIS1-deleted cells (Figure 6A and Movie S2). Thus, MEIS1
deletion completely abolishes thrombopoiesis. In keeping
with the results from MEIS1-deleted cells, many fewer pro-
platelets were produced from MEIS1+/ megakaryocytes
(Figure 6A). We next assessed platelet production directly
bymeasuring the percentages of PLPs collected from culture
supernatant at day 6 after differentiation. Consistent with
the earlier findings, CD41a+CD42b+ PLPs were nearly unde-
tectable from culture supernatant of megakaryocytes with
MEIS1 deletion (H1 hESCs 57.26% ± 6.13% versus 4.53% ±
0.57%; BC1 cells 45.38% ± 4.33% versus 2.90% ± 1.81%;
p < 0.01) (Figure 6B).
To exclude the possibility that the decreased megakaryo-
cytic differentiation might result from earlier HEP defects
caused by MEIS1 deletion, we depleted MEIS1 directly in
CD43+ HPCs using small hairpin RNAs (shRNAs) and deter-
mined the impact on megakaryocytic differentiation and





Figure 6. MEIS1 Deletion Completely Ab-
rogates Thrombopoiesis
(A) The morphology of representative pro-
platelets at day 6 of megakaryocytic dif-
ferentiation (scale bar, 20 mm).
(B) Flow cytometry analysis of the per-
centage of CD41a+CD42b+ PLPs in the cul-
ture supernatant at day 6 of megakaryocytic
differentiation.
(C) Generation of CD41a+CD42b+ megakar-
yocytes from HPCs with MEIS1 depletion
induced by shMEIS1-651 or shMEIS1-1088.
A scramble shRNA was used as a control.
(D) Generation of CD41a+CD42b+ PLPs
derived from HPCs without or with MEIS1
depletion.
(E) Phase-contrast images of proplatelet
formation from WT and MEIS1-deleted hPSCs
without or with MEIS1 overexpression.
Cells were cultured on plates precoated
with 100 mg/mL fibrinogen for convenient
observation. Vector carrying GFP was used as
a control (scale bar, 20 mm).
(F) Flow cytometry analysis of the percent-
age of CD41a+CD42b+ PLPs derived from WT
and MEIS1-deleted hPSCs without or with
MEIS1 overexpression.
Error bars represent mean ± SEM of samples
from three independent experiments. NS,
not significant, *p < 0.05, **p < 0.01,
***p < 0.001. MK, megakaryocytic.
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from CD43+ HPCs caused the same phenotype as observed
inMEIS1-knocked-out H1 hESCs (Figures 6C, 6D, and S6F).
These results indicated that MEIS1 deletion indeed
impaired megakaryopoiesis and thrombopoiesis, indepen-
dent of the earlier HEP defects.
To further confirm that the deficiency in thrombopoiesis
was due to the loss of MEIS1, we determined whether
MEIS1 ectopic expression could rescue the defects caused
by MEIS1 deletion (Figure S6G). As shown in Figures 6E
and 6F, overexpression of MEIS1 in WT HPCs failed to
further improve the efficiency of platelet generation. In
contrast, overexpression ofMEIS1markedly increased gen-
eration of PLPs from MEIS1/ HPCs. Strikingly, there was
no statistical difference between WT and MEIS1/cells
when MEIS1 was overexpressed. Together, we provide
evidence for an essential role of MEIS1 in human
thrombopoiesis.
MEIS1 Controls Megakaryocytic Specification by
Enhancing FLI1 Expression
We next assessed the mechanism by which MEIS1 controls
megakaryocytic maturation and thrombopoiesis. We con-
ducted RNA-seq analysis, aiming to identify the down-
stream targets that mediate the function of MEIS1. We
detected several hundreds of downregulated genes in cells
with MEIS1 deletion (p < 0.001, FDR< 0.001, Table S5).
GO analysis showed that 8 of the top 10 most significant
biological processes were associated with platelet functions
(Figure 7A). The GSEA based on KEGG gene sets also
showed significant enrichment in platelet-specific genes
in WT cells, whereas such enrichment was not seen in
MEIS1-deleted cells (Figure S7A). The results from large-
scale genomic analysis again demonstrated the reliability
of our platelet generation system and verified that MEIS1
deletion indeed severely impairs thrombopoiesis.
Among the genes with significantly altered expression, a
number of hematopoiesis-associated genes such as PBX1
and FLI1 were identified (Figure 7B and Table S5). We
focused on FLI1 because of its previously reported roles in
megakaryopoiesis (Li et al., 2015). Real-time PCR analysis
confirmed downregulation of FLI1 in MEIS1-deleted H1
hESCs and BC1 cells (Figure 7C). We then tested the func-
tion of FLI1 by overexpressing FLI1-P2A-GFP by using the
lentivirus system (Figure S7B). Ectopic expression of FLI1
was confirmed by real-time PCR and western blot analysis
(Figures S7C and S7D). Remarkably, FLI1 overexpression
nearly completely rescued the decrease in CD41a+CD42b+
megakaryocytes and the reduction in cell sizes caused by
MEIS1 deletion in H1 hESCs and BC1 cells (Figures 7D
and S7E). Thus, FLI1 is vital to mediate the function of
MEIS1 during megakaryopoiesis. Interestingly, in contrast
to the strong effect in rescuing megakaryocytic differentia-
tion, FLI1 overexpression only moderately reversed the de-
fects in proplatelet generation caused by MEIS1 deletion
(Figures 7E and S7F), suggesting that FLI1 only partially
mediates the function of MEIS1 during thrombopoiesis.
DISCUSSION
In summary, we identifiedMEIS1 as a potential regulator of
hPSC early hematopoietic differentiation. MEIS1 controls
specification of APLNR+ mesoderm progenitors to HEPs,
and TAL1 mediates this function of MEIS1. In addition,
MEIS1 is vital for megakaryocytic differentiation, poly-
ploidization, and subsequent platelet production from
hPSCs. FLI1 acts as a downstream gene necessary for the
function of MEIS1 during megakaryopoiesis and thrombo-
poiesis (Figure 7F). Together, we define a role of MEIS1 in
human development, unveil new mechanisms for human
hematopoiesis, and contribute potential new strategies to
regenerative medicine.
In addition to its function as an accelerator in the patho-
genesis of leukemia, MEIS1 has been shown to play crucial
roles in normal hematopoietic development. Embryonic
lethality at day 14.5 and hematopoietic, vascular, and
retinal defects were observed in MEIS1-deleted homozy-
gous animals (Azcoitia et al., 2005; Gonzalez-Lazaro et al.,
2014; Hisa et al., 2004). Meis1 conditional knockout in
adult mice also caused defects in adult erythropoiesis, meg-
akaryopoiesis, andHSCmaintenance (Ariki et al., 2014; Ko-
cabas et al., 2012; Miller et al., 2016; Unnisa et al., 2012).
Despite these animal studies, the role of MEIS1 in human
early development has not been reported to date. Further-
more, how MEIS1 controls early hematopoiesis is even
less understood. Here by using the CRISPR/CAS9 technol-
ogy, we successfully created MEIS1 knockout cell lines in
hPSCs, leading us to define an essential role for MEIS1 in
human early hematopoiesis. In addition, we performed a
detailed analysis of the potential function ofMEIS1 in early
hematopoietic development and presented evidence for a
critical and specific role of MEIS1 in transition of APLNR+
cells to CD31+CD34+ HEPs. Thus, the HSC decrease
observed in vivo in Meis1 knockout animals might also
result from the decrease in HEP generation.
By performing large-scale gene profiling analysis and
subsequent functional studies, we identified TAL1 as the
downstream transcription factor that mediates the func-
tion of MEIS1 in controlling HEP generation. Although
the role of TAL1 as a master regulator in HEP generation
in hESCs has been reported (Real et al., 2012), we estab-
lished a functional link between MEIS1 and TAL1 and
unveiled a new signaling mechanism that controls early
hematopoiesis. Our results also suggest that MEIS1 acts as
another master regulator of HEP generation and does so
by acting upstream of TAL1.
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In addition to the defects in HEP generation, we also
identified defects in megakaryocytic differentiation and
platelet generation in cells withMEIS1 deletion, consistent
with the previously documented defects in megakaryocyte
lineage development in Meis1 mutant animals (Azcoitia
et al., 2005; Carramolino et al., 2010; Gonzalez-Lazaro
et al., 2014; Hisa et al., 2004). However, in contrast to the
in vivo observations, generation of CD41+ megakaryocytes
from human hPSCs was impaired but not completely abro-
gated. Instead, the primary defect caused by MEIS1 dele-
tion in our system was the failure of the cells to undergo
polyploidization. This function of MEIS1 has not been re-
ported earlier. Strikingly, nearly none of CD41+megakaryo-
cyte generated from MEIS1/ HPC can develop beyond
the 4N stage, while live-imaging analysis clearly demon-
strated that despite a small portion of CD41+ megakaryo-
cytes generated, no platelets can be produced from any
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Figure 7. MEIS1 Controls Megakaryo-
cytic Specification by Enhancing FLI1
Expression
(A) Top 10 biological functions of down-
regulated genes in cells with MEIS1 dele-
tion. RNA-seq analysis was performed on
samples collected from at day 0, day 3, and
day 6 of megakaryocytic differentiation.
(B) Heatmaps of top 20 downregulated
transcriptional factors in cells with MEIS1
deletion during megakaryocytic differenti-
ation from H1 hESCs.
(C) Real-time PCR analysis of FLI1 in cells
differentiated from WT and MEIS1-deleted
hPSCs during megakaryocytic differentia-
tion. GAPDH was an internal control. All
values were normalized to the level (= 1) of
mRNA in the cells derived from WT hPSCs.
(D) Flow cytometry analysis of the per-
centage of CD41a+CD42b+ megakaryocytes
differentiated from WT and MEIS1-deleted
hPSCs without or with FLI1 overexpression.
GFP+ gated events are shown.
(E) Flow cytometry analysis of the per-
centage of CD41a+CD42b+ PLPs differenti-
ated from WT and MEIS1-deleted hPSCs
cultured on plates precoated with fibrin-
ogen without or with FLI1 overexpression.
GFP+ gated events are shown.
(F) A working model for MEIS1 function and
mechanism in hPSC early hematopoietic and
megakaryocytic differentiation. LPM, lateral
plate mesoderm; HEP, hemogenic endothe-
lium progenitor; MKP, megakaryocyte pro-
genitor; MK, megakaryocyte; PLT, platelet.
Error bars represent mean ± SEM of samples
from three independent experiments. NS,
not significant, *p < 0.05.
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to an equally important role for MEIS1 in thrombopoiesis
aside from its function in megakaryopoiesis. Together,
our studies markedly extend previous findings that overex-
pression ofMEIS1 enhancesMEP generation (Zeddies et al.,
2014), providing the direct evidence for a critical and spe-
cific function of MEIS1 in megakaryocyte polyploidization
and platelet derivation. At the mechanistic level, we found
that FLI1 acts downstream of MEIS1 to mediate the func-
tion of MEIS1 in megakaryopoiesis and thrombopoiesis.
Interestingly, FLI1 overexpression nearly completely
rescued differentiation of CD41+ megakaryocytes but
only partially increased platelet generation. Thus, a more
complete delineation of the detailed mechanisms underly-
ing MEIS1’s actions awaits future studies.
hPSCs have long been recognized as a potential source
for large-scale platelet generation in vitro for transfusion,
and large numbers of megakaryocytes can indeed be
derived from hiPSCs via reprogramming with various
gene combinations (Sim et al., 2016). Our findings high-
light the stage-specific functional significance of MEIS1,
TAL1, and FLI1 transcription factors during early hemato-
poiesis, megakaryopoiesis, and thrombopoiesis. This
knowledge can be proved invaluable for manipulating
cell fate during hematopoietic differentiation and for




Umbilical cordblood (CB) units were obtained from healthy full-
term neonates with informed consent from the parents and
approved by the ethics committee of the Institute of Hematology
and Blood Diseases Hospital, Chinese Academy of Medical Sci-
ences. CD34+ cells were isolated from CB using Ficoll-Hypaque
density centrifugation medium (Sigma-Aldrich, St. Louis, MO)
and MiniMACS CD34+ isolation kit (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to themanufacturer’s instructions.
hPSC Hematopoietic Differentiation in Chemically
Defined Conditions
hPSC hematopoietic differentiation was carried out under chemi-
cally defined conditions as previously described with somemodifi-
cation (Pang et al., 2013; Wang et al., 2012). hPSCs were dissoci-
ated into a single-cell suspension using 1 mg/mL Accutase
(Gibco) and plated on Matrigel-coated dishes at a density of
3.5 3 104 cells/well (12-well plate) in mTeSR1 medium with
10 mM Y27632 (Calbiochem). After 24 hr, hPSCs were induced
for stepwise differentiation. First, cells were cultured in Custom
mTeSR1 medium supplemented with 40 ng/mL activinA (Pepro-
tech) and 50 ng/mL BMP4 (Peprotech) for 2 days. Second, cells
were incubated with Custom mTeSR1 medium supplemented
with 40 ng/mLVEGF (Peprotech) and 50 ng/mL bFGF (Peprotech)
for 2 days. Third, cells were incubated with Custom mTeSR1
medium supplemented with 40 ng/mL VEGF, 50 ng/mL bFGF,
and 20 mM SB 431542 (STEMGENT) for 3 days. Finally, differenti-
ated cells were transferred to low-attachment plates and cultured
for 6 days inmTeSR1mediumcontaining50ng/mL stem cell factor
(SCF) (Peprotech), 50 ng/mLTPO (Peprotech) and 50 ng/mL inter-
leukin-3 (IL-3) (Peprotech), 1 mM GlutaMAX (Gibco), 2% B27
(Gibco), 0.1 mM monothioglycerol (Sigma-Aldrich), 1% insulin-
transferrin-selenium (Gibco), 1% N-acetylaspartate (Gibco), 1%
penicillin/streptomycin.
hPSC Hematopoietic Differentiation in the mAGM-S3
Co-culture
Hematopoietic differentiation of hPSCs co-cultured with the
AGM-S3 cells was performed as previously described (Mao et al.,
2016). Before co-culture with hPSCs, mAGM-S3 cells were grown
to form an overgrown monolayer and treated with 5 ng/mL mito-
mycinC (Sigma-Aldrich) at 37C for 2 hr. The hPSCswere prepared
as a suspension of small aggregates using 2 U/mL dispase and
plated on inactivated mAGM-S3 cells at a density of 20–30 aggre-
gates/well (six-well plate) in mTeSR1 medium. On the next day,
the medium was replaced with Iscove’s modified Dulbecco’s me-
dium supplemented with 10% fetal bovine serum (Gibco/Life
Technologies), 15 ng/mL VEGF (Peprotech), 1% nonessential
amino acid solution (Gibco), 100 mM 2-mercaptoethanol (Sigma-
Aldrich) and 1 mM L-glutamine (Gibco), 50 mg/mL L-ascorbic
acid (Sigma-Aldrich), 7 mg/mL human transferrin (Sigma-Aldrich).
The medium was changed every day.
Megakaryocytic Differentiation from hPSCs
After 10 days of hematopoietic differentiation of hPSCs under the
mAGM-S3 co-culture, cobblestone-like cells weremechanically de-
tached and replated onto mitotically inactivated mAGM-S3 cells
in the hematopoietic differentiation medium plus Y-27632
(10 mM), TPO (50 ng/mL), SCF (20 ng/mL), IL-3 (20 ng/mL), IL-6
(10 ng/mL), IL-9 (20 ng/mL), and IL-11 (20 ng/mL, Peprotech).
Fresh medium was used every 3 days.
Establishing MEIS1 Knockout hPSC Lines Using
CRISPR/CAS9 Technology
Lentivirus containing MEIS1-E3G1 was infected into H1 hESCs or
BC1 hiPSCs, which were subsequently selected with puromycin
(1 mg/mL, Sigma). After the genome editing efficacy was accessed
using Surveyor assay, the cells were dissociated into single cells
with Accutase (Gibco). Small colonies emerging from single cells
were picked and expanded. MEIS1 knockout hESC lines were
identified using western blotting assays and gene-sequencing
analysis.
RNA-Seq
RNA-seq analysis was performed by BGI Company (BGI, Shenz-
hen, China) as previously described. The mRNA expression levels
were visualized with a heatmap built based on the value of log10
(fragments per kilobase of transcript per millionmapped reads + 1)
using MultiExperiment Viewer v.4.2. GO enrichment was per-
formed using Gene Ontology (http://geneontology.org/). The re-
sults are available at Gene Expression Omnibus (GEO: GSE92245).
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Lentivirus Production and Infection
Lentiviruses for gene knockdown or overexpression were packaged
using the Viralpower Lentivirus Packaging System (Invitrogen) ac-
cording to the manufacturer’s instruction. For early hematopoiesis,
lentivirus for MEIS1 or TAL1 was added into mTeSR1 medium
with small colonies of hPSCs and Polybrene (3 mg/mL) for 96 hr
before the hematopoietic differentiation of hPSCs. Then GFP+ cells
(43 104/mL) were sorted for further hematopoietic differentiation.
For megakaryopoiesis, lentivirus forMEIS1 or FLI1 was mixed with
hematopoietic differentiation medium with HPCs and Polybrene
(6 mg/mL) for 10hr. Then themegakaryocyticmediumwas changed
to fresh and cells were replated onto mitotically inactivated
mAGM-S3 stromal cells for further differentiation. GFP+ events
were gated to analyze the megakaryocytic potential every 3 days.
Statistical Analysis
At least three independent experiments were performed for each
analysis, and two-tailed Student’s t test was used to compare the
differences between two groups using the GraphPad Prism soft-
ware. All data are expressed as the mean ± SD. Differences were
considered statistically significant when p < 0.05.
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